NCT05860296
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05860296
Title Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors SignalChem Lifesciences Corporation
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Community Health Network Indianapolis Indiana 46250 United States Details
Horizon Verdi Oncology Lafayette Indiana 47905 United States Details
Karmanos Cancer Center Detroit Michigan 48201 United States Details
Nebraska Cancer Specialists Omaha Nebraska 68130 United States Details
Cleveland Clinic Cleveland Ohio 44195 United States Details
Stephenson Cancer Center Oklahoma City Oklahoma 73104 United States Details
Cross Cancer Institute Edmonton Alberta Canada Details
Juravinski Cancer Centre Hamilton Ontario Canada Details
London Regional Cancer Centre London Ontario Canada Details
Sunnybrook Health Sciences Centre Toronto Ontario Canada Details
Jewish General Hospital Montreal Quebec H3T 1E2 Canada Details
McGill University Health Centre Montreal Quebec H4A 3J1 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field